158 related articles for article (PubMed ID: 36738874)
41. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
42. [Diagnosis of urothelial carcinoma].
Karl A; Zaak D; Tilki D; Hungerhuber E; Staehler M; Denzinger S; Stanislaus P; Tritschler S; Strittmatter F; Stief C; Burger M
Urologe A; 2008 Mar; 47(3):357-67. PubMed ID: 18274722
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of mucin expression in urothelial bladder cancer.
Stojnev S; Ristic-Petrovic A; Velickovic LJ; Krstic M; Bogdanovic D; Khanh do T; Ristic A; Conic I; Stefanovic V
Int J Clin Exp Pathol; 2014; 7(8):4945-58. PubMed ID: 25197366
[TBL] [Abstract][Full Text] [Related]
44. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
45. Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.
El-Gendi S; Abu-Sheasha G
Pathol Oncol Res; 2018 Apr; 24(2):309-322. PubMed ID: 28488128
[TBL] [Abstract][Full Text] [Related]
46. [Prognostic factors in urothelial carcinoma].
Vögeli TA; Ackermann R
Urologe A; 2001 Nov; 40(6):442-6. PubMed ID: 11760346
[TBL] [Abstract][Full Text] [Related]
47. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
48. Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer.
Zaidi N; Siddiqui Z; Sankhwar SN; Srivastava AN
J Cancer Res Ther; 2023; 19(5):1324-1329. PubMed ID: 37787302
[TBL] [Abstract][Full Text] [Related]
49. Current Use and Promise of Urinary Markers for Urothelial Cancer.
Tabayoyong W; Kamat AM
Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer.
Silén A; Rizvi SS; Letocha H; Lennernäs B; Wiklund B
Oncol Rep; 2000; 7(6):1269-74. PubMed ID: 11032928
[TBL] [Abstract][Full Text] [Related]
51. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder.
Sumi S; Arai K; Kitahara S; Yoshida KI
Clin Chim Acta; 2000 Jun; 296(1-2):111-20. PubMed ID: 10807975
[TBL] [Abstract][Full Text] [Related]
52. Proteomic research and diagnosis in bladder cancer: state of the art review.
Wilson JL; Antoniassi MP; Lopes PI; Azevedo H
Int Braz J Urol; 2021; 47(3):503-514. PubMed ID: 32459456
[TBL] [Abstract][Full Text] [Related]
53. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.
Ather MH; Nazim SM
Korean J Urol; 2015 Aug; 56(8):553-64. PubMed ID: 26279824
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
55. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
56. Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer.
Agreda Castañeda F; Raventós Busquets CX; Morote Robles J
Clin Genitourin Cancer; 2020 Jun; 18(3):230-235. PubMed ID: 31911121
[TBL] [Abstract][Full Text] [Related]
57. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
[TBL] [Abstract][Full Text] [Related]
58. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
[TBL] [Abstract][Full Text] [Related]
59. Novel urinary biomarkers for the detection of bladder cancer: A systematic review.
Tan WS; Tan WP; Tan MY; Khetrapal P; Dong L; deWinter P; Feber A; Kelly JD
Cancer Treat Rev; 2018 Sep; 69():39-52. PubMed ID: 29902678
[TBL] [Abstract][Full Text] [Related]
60. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
Sánchez-Carbayo M; Urrutia M; Hernández-Cerceño ML; González de Buitrago JM; Navajo JA
Med Clin (Barc); 2000 Mar; 114(10):361-6. PubMed ID: 10786344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
